Publications

Show Filters

Searches all publications.

Search Fulltext

Publications

Section

Select publication to see the relevant sections.

Publication Date

    E.g., 2018-06-25
    E.g., 2018-06-25

Articles

172682 items
12:15 PM, Jun 22, 2018  |  BC Week In Review | Financial News  |  Completed Offerings

IPO roundup: Avrobio, Aptinyx, Magenta, Kezar, Xeris

Five biopharmas priced IPOs late on June 20, raising a total of more than $460 million. Four of the five upsized their offerings to sell more shares than anticipated; one of those, Avrobio, also priced...
12:14 PM, Jun 22, 2018  |  BC Week In Review | Company News  |  Deals

J&J opens JLABS incubator in NYC

The Johnson & Johnson Innovation LLC subsidiary of Johnson & Johnson (NYSE:JNJ) opened JLABS@NYC, a JLABS incubator in New York City, with 26 resident companies. Resident companies at JLABS include the four winners of the JLABS@NYC...
12:14 PM, Jun 22, 2018  |  BC Week In Review | Clinical News  |  Clinical Results

Merck reports Phase II data for Keytruda in SCLC

Merck & Co. Inc. (NYSE:MRK) reported interim data from a cohort of 107 evaluable patients with advanced small cell lung cancer (SCLC) in the Phase II KEYNOTE-158 trial showing that Keytruda pembrolizumab led to an...
12:14 PM, Jun 22, 2018  |  BC Week In Review | Clinical News  |  Clinical Results

Merck reports Phase II data for Keytruda as first-line RCC therapy

Merck & Co. Inc. (NYSE:MRK) reported interim data from 110 evaluable patients with advanced clear cell renal cell carcinoma (RCC) in the Phase II KEYNOTE-427 trial showing that first-line treatment with Keytruda pembrolizumab led to...
12:03 PM, Jun 22, 2018  |  BC Week In Review | Financial News  |  Completed Offerings

ObsEva raises $73M follow-on

Reproductive health company ObsEva S.A. (NASDAQ:OBSV) raised $73.1 million through the sale of 4.8 million shares at $15.39 in a follow-on underwritten by J.P. Morgan, Credit Suisse Securities (USA), Jefferies, Wedbush Securities and H.C. Wainwright....
12:03 PM, Jun 22, 2018  |  BC Week In Review | Financial News  |  Completed Offerings

Syncona leads Freeline's £88M series B

Freeline Therapeutics Ltd. (London, U.K.) raised £88.4 million ($116.9 million) on June 19 in a series B round which included £85 million from lead investor Syncona Ltd. (LSE:SYNC). Fellow founding investor UCL Technology Fund also...
12:02 PM, Jun 22, 2018  |  BC Week In Review | Clinical News  |  Regulatory

FDA restricts Keytruda, Tecentriq monotherapy

FDA restricted the labels of Keytruda pembrolizumab and Tecentriq atezolizumab as monotherapy for urothelial cancer in a first-line setting. The update applies to Keytruda or Tecentriq's use in locally advanced or metastatic urothelial carcinoma to patients...
12:02 PM, Jun 22, 2018  |  BC Week In Review | Financial News  |  Completed Offerings

Aminex raises $10M, starts Phase I cancer trial

Aminex Therapeutics Inc. (Seattle, Wash.) raised $10 million on June 20 in an untranched series B round. The company declined to name its investors. The company also said it dosed the first patient in a Phase...
12:02 PM, Jun 22, 2018  |  BC Week In Review | Financial News  |  Completed Offerings

Verrica shares jump after $75M IPO

Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) added $2.50 (17%) to $17.50 in its first day of trading June 15 after the dermatology company raised $75 million through the sale of 5 million shares at $15 in an...
12:01 PM, Jun 22, 2018  |  BC Week In Review | Financial News  |  Completed Offerings

Oncology play iTeos raises $75M, outlines clinical plans

iTeos Therapeutics S.A. (Gosselies, Belgium) raised $75 million on June 19 in a series B round led by MPM Capital. Also participating in the round were HBM Partners, 6 Dimensions Capital, Curative Ventures and SFPI as...

Pages